WallStSmart

Artivion Inc (AORT)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 13882% more annual revenue ($67.38B vs $481.88M). MRK leads profitability with a 3.6% profit margin vs -3.6%. MRK appears more attractively valued with a PEG of 2.82. MRK earns a higher WallStSmart Score of 44/100 (D).

AORT

Hold

35

out of 100

Grade: F

Growth: 6.0Profit: 3.0Value: 3.0Quality: 6.5
Piotroski: 4/9Altman Z: 1.46

MRK

Hold

44

out of 100

Grade: D

Growth: 3.3Profit: 6.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AORTSignificantly Overvalued (-28.3%)

Margin of Safety

-28.3%

Fair Value

$31.25

Current Price

$19.40

$11.85 premium

UndervaluedFair: $31.25Overvalued
MRKSignificantly Overvalued (-72.9%)

Margin of Safety

-72.9%

Fair Value

$84.87

Current Price

$146.99

$62.12 premium

UndervaluedFair: $84.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AORT1 strengths · Avg: 8.0/10
Price/BookValuation
2.1x8/10

Reasonable price relative to book value

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$368.89B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
41.2%10/10

Strong operational efficiency at 41.2%

Free Cash FlowQuality
$5.52B8/10

Generating 5.5B in free cash flow

Areas to Watch

AORT4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$998.73M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
4.9%3/10

Operating margin of 4.9%

PEG RatioValuation
181.502/10

Expensive relative to growth rate

MRK4 concerns · Avg: 3.5/10
Price/BookValuation
8.7x4/10

Trading at 8.7x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Return on EquityProfitability
5.5%3/10

ROE of 5.5% — below average capital efficiency

Profit MarginProfitability
3.6%3/10

3.6% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AORT

The strongest argument for AORT centers on Price/Book.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : AORT

The primary concerns for AORT are EPS Growth, Market Cap, Operating Margin.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.

Key Dynamics to Monitor

AORT profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

AORT carries more volatility with a beta of 1.28 — expect wider price swings.

AORT is growing revenue faster at 9.2% — sustainability is the question.

MRK generates stronger free cash flow (5.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (44/100 vs 35/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Artivion Inc

HEALTHCARE · MEDICAL DEVICES · USA

Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?